Cargando…
Cancer immunotherapy by immunosuppression
We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018371/ https://www.ncbi.nlm.nih.gov/pubmed/21159199 http://dx.doi.org/10.1186/1742-4682-7-45 |
_version_ | 1782196049441456128 |
---|---|
author | Prehn, Richmond T Prehn, Liisa M |
author_facet | Prehn, Richmond T Prehn, Liisa M |
author_sort | Prehn, Richmond T |
collection | PubMed |
description | We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing cancer, whether in man or mouse, is throughout its lifespan, probably growing and progressing because of continued immune stimulation by a weak immune reaction. We also suggest that prolonged immunosuppression might interfere with progression and thus be an aid to therapy. While most of the considerable evidence that supports the hypothesis comes from observations of experimental mouse tumors, there is suggestive evidence that human tumors may behave in much the same way, and as far as we can ascertain, there is no present evidence that necessarily refutes the hypothesis. |
format | Text |
id | pubmed-3018371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30183712011-01-11 Cancer immunotherapy by immunosuppression Prehn, Richmond T Prehn, Liisa M Theor Biol Med Model Commentary We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing cancer, whether in man or mouse, is throughout its lifespan, probably growing and progressing because of continued immune stimulation by a weak immune reaction. We also suggest that prolonged immunosuppression might interfere with progression and thus be an aid to therapy. While most of the considerable evidence that supports the hypothesis comes from observations of experimental mouse tumors, there is suggestive evidence that human tumors may behave in much the same way, and as far as we can ascertain, there is no present evidence that necessarily refutes the hypothesis. BioMed Central 2010-12-15 /pmc/articles/PMC3018371/ /pubmed/21159199 http://dx.doi.org/10.1186/1742-4682-7-45 Text en Copyright ©2010 Prehn and Prehn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Prehn, Richmond T Prehn, Liisa M Cancer immunotherapy by immunosuppression |
title | Cancer immunotherapy by immunosuppression |
title_full | Cancer immunotherapy by immunosuppression |
title_fullStr | Cancer immunotherapy by immunosuppression |
title_full_unstemmed | Cancer immunotherapy by immunosuppression |
title_short | Cancer immunotherapy by immunosuppression |
title_sort | cancer immunotherapy by immunosuppression |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018371/ https://www.ncbi.nlm.nih.gov/pubmed/21159199 http://dx.doi.org/10.1186/1742-4682-7-45 |
work_keys_str_mv | AT prehnrichmondt cancerimmunotherapybyimmunosuppression AT prehnliisam cancerimmunotherapybyimmunosuppression |